Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Metabolic Disease Drug Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PGK1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PGK1 Recombinant Protein (Human, Mouse, Cyno) High purity (>95%), Endotoxin controlled. Sequence Verified. Available in E. coli or HEK293 expression systems. |
View PGK1 Products |
| Gene Delivery | PGK1 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and overexpression validation. |
View PGK1 Products |
| Benchmark Ab | Anti-PGK1 Recombinant Antibody High-affinity clone verified for Western Blot, IHC, and ELISA positive controls. |
View PGK1 Products |
| Validator | PGK1 siRNA Set Target-specific knockdown pool for functional assay validation. |
View PGK1 Products |
| Related Target A | PKM2 Rate-limiting glycolytic enzyme; synergistic target for metabolic reprogramming in tumor microenvironments. |
View PKM2 Products |
| Related Target B | LDHA Downstream metabolic driver; crucial for validating lactate pathway inhibition. |
View LDHA Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selectivity over PGK2 homolog | Recombinant PGK1 and PGK2 homolog proteins available with verified sequence identity and purity >95% for counter-screening. |
| Intracellular vs. Extracellular Assay Design | Active E. coli-expressed PGK1 for enzymatic screening; HEK293-expressed PGK1 for native glycosylation to study secreted disulfide reductase activity. |
| Lack of Controls | Clinical benchmark antibodies and sequence-verified positive controls included. |
| False Positives in Small Molecule Screen | Validated siRNA sets included for target knockdown and specificity verification in cell-based assays. |
Live PGK1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PGK1 therapeutics is intensifying, with major players shifting focus from traditional global metabolic inhibitors to highly selective small-molecule inhibitors and targeted protein degraders (PROTACs). As first-generation metabolic therapies reach clinical trial stages, the next wave of R&D is targeting the dual-role of PGK1: its intracellular role in glycolysis and its extracellular function as a disulfide reductase promoting angiogenesis.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic spin-offs, Biotech startups | Solid Tumors (Breast, Gastric, Pancreatic) | Enzymatic activity assays and selectivity panels (Need high-purity recombinant PGK1 and PGK2) |
| PROTACs / Degraders | Targeted Protein Degradation specialists | Metastatic Cancers, Chemoresistant Tumors | Target engagement and ternary complex validation (Need high-purity tagged PGK1) |
| Monoclonal Antibodies | Immunotherapy developers | Angiogenesis-driven Solid Tumors | Secreted functional assays (Need HEK293-expressed PGK1 with native post-translational modifications) |